Pfizer Commences New Biotech Facility In Sweden
Company invested $214.8m in the plant at Strangnas
Pfizer has opened a new biotech facility in Sweden, which will be used to make products including a branded version of human growth hormone.
The company said that it has invested $214.8m in the plant at Strangnas. The 6,000 square meters facility is likely to manufacture Pfizer's human growth hormone, or Genotropin, along with the drug Somavert for acromegaly, and drugs based on E. coli and yeast.
Genotropin, a growth hormone treatment, has been proven to be safe and effective. Genotropin has been approved by the FDA to treat growth failure in: children with growth hormone deficiency (GHD), children with Prader-Willi syndrome (PWS), children born small for gestational age (SGA), girls with Turner syndrome (TS), children with Idiopathic Short Stature (ISS), and adults with growth hormone deficiency (aGHD).
Related Insight
Suppliers Directory
Avicor - Affinity Chromatography and Chemical Microarray Drug Discovery Services
Avicor provides key technologies for the early phase of drug discovery with chemical microarrays, chemoproteomics and interaction-based HTS.
Suppliers
Asterand - Human Tissue and Human Tissue-Based Research Services
Asterand plc is the leading global supplier of high quality, well characterised human tissue and human tissue-based research services to drug discovery scientists.
Suppliers
Optima Group pharma - Filling and Packaging Machines for Syringes, Vials, Bottles and Carpules Products
Optima Group Pharma consists of four top-quality brands: Inova, Klee, Kugler and Metall + Plastic. Thanks to years of specializing, the Optima Group Pharma offers a comprehensive, cutting-edge range of products. This includes the filling and packaging of pharmaceutical liquids and powders, combined production and packaging lines for medical/ pharmaceutical products as well as automation and laboratory processes. Additionally the designing, manufacturing, installation and validation of state-of-the-art isolation and containment technology are also part of the portfolio.
Suppliers
Pharmaceutical Development Services - Pharmaceutical, Regulatory and Medical Device Consultancy
Pharmaceutical Development Services (PDS) is a pharmaceutical and regulatory consultancy serving the pharmaceutical, biopharmaceutical, medical device and cosmetic industries. We provide expert advice on drug development and production strategy including the development, supply and regulatory control of new and existing pharmaceutical products.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Polymeric Nanofibers, Nanofibrous Layers, Nanofiber Yarns and Nanoparticles
Published by Phenom World
White Papers
A New Approach to Outsourced Drug Development
Published by INC Research
White Papers
Make time for science with the Rocket
Published by Genevac
White Papers
Efficacy and Surgical Research Services (ESRS)
Published by Toxikon Europe
Contract Research & Services > Contract Research > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.